Do mushroom and protein 'functional' coffees have health benefits?

Functional coffees — drinks boosted with ingredients such as mushroom powders (lion's mane, reishi), collagen and protein — are moving from health-food niches into mainstream high-street menus, with Tastewise naming it a top 2026 trend and mushroom coffees on UK menus up ~30% year-on-year; chains and retailers from Starbucks and Holland & Barrett to Black Sheep Coffee are rolling out offerings and add-ons, with Black Sheep reporting functional add-ons on ~15% of orders and typical add-on prices around £0.99–£1.09 (Starbucks $1–$2), implying meaningful incremental spend (roughly £30/month for daily buyers). While consumer anecdotes of improved focus and reduced jitters are driving demand and premiumisation opportunities for operators, nutritionists and dietitians caution that clinical evidence is limited, typical doses on menus are likely too small to replicate trial results, and benefits are not essential for most consumers — creating short-term revenue and margin upside but uncertainty over long-term, evidence-based adoption and regulatory/quality risks.

Analysis

Functional coffees — beverages enhanced with mushroom powders (lion's mane, reishi, chaga), collagen and protein — are migrating from health-food stores to mainstream high-street menus, with Tastewise naming the category a top trend for 2026 and the number of mushroom coffees on UK coffee shop menus up roughly 30% year-on-year. Major retailers and operators are participating: Holland & Barrett has almost doubled its mushroom-coffee range, Starbucks introduced barista-made protein coffee in US stores in September and sells bottled protein coffee in shops and supermarkets, and independents such as Sipp and chains like Black Sheep report strong consumer uptake. Black Sheep states functional add-ons account for about 15% of coffee, matcha and smoothie orders and charges roughly £0.99–£1.09 per add-on (Starbucks charges $1–$2), implying potential incremental spend of ~£30/month for daily buyers and positive AUV/margin implications for operators. Clinical evidence remains limited: multiple nutritionists and dietitians in the article caution that typical menu doses are likely too low to replicate trial effects, quality varies, and benefits are not essential for most consumers — creating a near-term revenue and premiumisation opportunity but material uncertainty on sustained, evidence-based adoption and regulatory or quality risk.

Key Decisions for Investors

• Consider selective exposure to large, diversified coffee operators (eg, SBUX) that can monetize add-on pricing and scale product launches given reported $1–$2 attach pricing and Black Sheep's ~15% attach rate,
• Monitor attach-rate and AUV data closely for signs of sustained consumer willingness to pay (watch month-over-month trends and promotions that reveal price elasticity),
• Limit exposure to small pure-play functional-beverage names or supplement suppliers until clinical efficacy, standardised dosing and quality controls are clearer,
• Track regulatory guidance and published clinical studies on lion's mane and other functional ingredients as key catalysts that could materially widen or narrow adoption and re-rate valuation assumptions